Zur Merkliste hinzufügen


44814-01 - Vorlesung: Target Validation and Identification of Modulators in Immunopharmacology 1 KP

Semester Herbstsemester 2024
Angebotsmuster Jedes Herbstsemester
Dozierende Christoph Burkhart (christoph.burkhart@unibas.ch)
Thomas Calzascia (thomas.calzascia@unibas.ch)
Tobias Junt (tobias.junt@unibas.ch, BeurteilerIn)
Gisbert Weckbecker (gisbert.weckbecker@unibas.ch)
Lernziele The student will understand:
- Concepts of basic immunology as a prerequisite for discovery of novel targets and drugs
- Medical need in key immunological disorders such as multiple sclerosis, lupus and transplant rejection
- Discovery, use and limitations of immunosuppressive drugs
- Cell depletion strategies to interfere with autoimmune disorders
- Discovery of immunomodulatory drugs, e.g. interference with cell migration, co-stimulation and nucleic acid sensing
- Immune activation as a successful treatment option for cancer and infection
- PI3 kinase inhibitors as an opportunity to interfere with immune disorders or cancer (e.g. idelalisib and duvelisib)
Literatur Literature List

Textbooks (in English):
• Kuby Immunology, 8th edition (2018)
• Janeway's Immunobiology, 10th edition (2022)
• Immunology. A Short Course. 8th Edition (2021), R. Coico G. Sunshine
• Cellular and Molecular Immunology, 10th Edition (2021), A. Abbas, A. Lichtman, S. Pillai

Check out “Global Immunotalks” on Youtube for related topics

Reviews and Papers:
Lectures 1 and 2 (Junt)

Edner NM, Carlesso G, Rush JS, Walker LSK., Targeting co-stimulatory molecules in autoimmune disease. Nat Rev Drug Discov. 2020 Dec;19(12):860-883
Junt T, Barchet W (2015), Translating nucleic acid-sensing pathways into therapies. Nat Rev Immunol 15, 529
Ley K et al (2016), Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov 15 (3), 173.
Chun J, Brinkmann VA (2011), Mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 12(64), 213.

Lectures 3 and 5 (Weckbecker)

Waring M et al (2015) An analysis of the attrition of drug candidates from four major pharmaceutical companies Nat Rev Drug Discov, online, 1.
Haijuan Y et al (2013) mTOR kinase structure, mechanism and regulation Nature 497, 217.
Gurk-Turner,C et al (2012) A Comprehensive Review of Everolimus Clinical Reports: A New Mammalian Target of Rapamycin Inhibitor Transplantation 94, 659.
Amber N. Carrier et al (2022) Xenotransplantation: A New Era (Review) Frontiers in Immunology 13, 1-11
B Sharrack, J Petrie, A Coles, JA Snowden (2022) Is stem cell transplantation safe and effective in multiple sclerosis? BMJ, 377.
Willison, A.G., Ruck, T., Lenz, G. et al. (2022) The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. J Neurol 269, 3937–3958.

Lecture 4 (Burkhart)

Vanhaesebroeck B et al (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11(5), 329.
Lucas C et al (2014) Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol 15, 88.
Rao VK et al (2017) Effective “activated PI3Kdelta syndrome”-targeted therapy with the PI3Kdelta inhibitor leniolisib. Blood 130, 2307
Vanhaesebroeck B et al (2021) PI3K inhibitors are finally coming of age. Nature Rev Drug Discov 20 (10), 471

Lecture 6 (Calzascia)

Ribas A and Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade, Science 359(6382), 1350
Chen DS and Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle, Immunity 39(1): 1.
Khalil DN et al (2016) The future of cancer treatment: immunomodulation, CARs and combination therapy, Nat Rev Clin Onc 13, 273.
Met Ö et al (2019) Principles of adoptive T cell therapy in cancer, Semin Immunopathol 41(1), 49
Fenis, A et al (2024) New immune cell engagers for cancer immunotherapy, Nat Rev Immunol, online AOP
Bemerkungen Researchers in Basel have contributed to the fields of immuno-pharmacology (e.g. cyclosporine, everolimus, ofatumumab, ocrelizumab, fingolimod, PI3 kinase inhibitors, diclofenac) and the lecture will refer to some of these discoveries

Film and sound recordings during the course are strictly forbidden (recorders may be confiscated)
Weblink Department of Pharmaceutical Sciences


Teilnahmebedingungen Completed Bachelor degree
Unterrichtssprache Englisch
Einsatz digitaler Medien kein spezifischer Einsatz


Intervall Wochentag Zeit Raum
wöchentlich Mittwoch 10.15-12.00 Biozentrum, Seminarraum U1.191


Datum Zeit Raum
Mittwoch 18.09.2024 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 25.09.2024 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 02.10.2024 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 09.10.2024 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 16.10.2024 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 23.10.2024 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 30.10.2024 13.45-14.45 Uhr Biozentrum, Hörsaal U1.141
Module Modul: Target Identification/Validation to Discovery of Modulators (Masterstudium: Drug Sciences)
Modul: Vertiefung Medizinische Nanowissenschaften (Masterstudium: Nanowissenschaften)
Wahlbereich Master Pharmazie: Empfehlungen (Masterstudium: Pharmazie)
Leistungsüberprüfung Lehrveranst.-begleitend
Hinweise zur Leistungsüberprüfung refer to this link: https://pharma.unibas.ch/en/education/assessments-and-credit-points/continuous-assessments/
An-/Abmeldung zur Leistungsüberprüfung Anm.: Belegen Lehrveranstaltung; Abm.: stornieren
Wiederholungsprüfung keine Wiederholungsprüfung
Skala 1-6 0,5
Wiederholtes Belegen beliebig wiederholbar
Zuständige Fakultät Philosophisch-Naturwissenschaftliche Fakultät, studiendekanat-philnat@unibas.ch
Anbietende Organisationseinheit Departement Pharmazeutische Wissenschaften